Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes

Abstract

The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

1 - 41 . (canceled)  
     
     
         42 . A method for treating diabetes or preventing the outbreak of diseases and conditions associated with diabetes comprising administering to a patient in need of such treatment or prevention a composition comprising nateglinide or a pharmaceutically acceptable salt thereof, sugar, and microcrystalline cellulose, wherein the sugar and microcrystalline cellulose are present in an amount of from 10-90 to 90-10 percent by weight respectively.  
     
     
         43 . The method according to claim  51  wherein the diabetes is type 2 diabetes.  
     
     
         44 . A method for decreasing the body weight of a mammal comprising administering to such mammal a composition comprising nateglinide or a pharmaceutically acceptable salt thereof, sugar, and microcrystalline cellulose, wherein the sugar and microcrystalline cellulose are present in an amount of from 10-90 to 90-10 percent by weight respectively.